Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 57Breast Neoplasms 35Neoplasms 32Parkinson Disease 4, Autosomal Dominant Lewy Body 25Multiple Myeloma 24Leukemia, Myeloid, Acute 20Recurrence 19Colorectal Neoplasms 17Neoplasm Metastasis 17Lymphoma, Non-Hodgkin 15Ovarian Neoplasms 15Carcinoma, Renal Cell 14Leukemia 14Leukemia, Lymphocytic, Chronic, B-Cell 14Melanoma 14Lymphoma, Follicular 12Lung Neoplasms 11Myelodysplastic Syndromes 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Urinary Bladder Neoplasms 11Carcinoma, Hepatocellular 10Hematologic Neoplasms 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Adenocarcinoma 9Glioma 9Lymphoma 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma, Mantle-Cell 9Prostatic Neoplasms 9Stomach Neoplasms 9

Interventions

luspatercept 1ibrutinib 1fludarabine phosphate 1Rituximab 1Pharmacogenomic Testing 1Cyclophosphamide 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Anemia × Clear all
NCT02048813 2026-05-01

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02631070 2021-12-17

MEDALIST

Celgene

Phase 3 Completed
229 enrolled 36 charts 1 FDA
Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡